Healthy
Conditions
Brief summary
To assess the bioequivalence of two galenic formulations for epinastine (Flurinol®): syrup and 20 mg tablets
Interventions
DRUGEpinastine syrup
DRUGEpinastine tablets
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* male and female, non-smoker and non-alcohol user, healthy volunteers, of 21 - 45 years of age. To be eligible, women must not be pregnant or lactating and they must not be taking hormone contraceptives * Volunteers must not have a history of liver or renal disease or a history of psychiatric disorder. Volunteers will be submitted to the biochemical tests listed below, the results of which must be within expected normal values: complete blood count, erythro-sedimentation rate, GOT (glutamate oxalacetate transaminase) GPT (glutamate pyruvate transaminase), blood creatinine, glycemia, uremia, blood cholesterol, pregnancy test. HIV test (with prior written consent), serum tests for Chagas disease, hepatic b and syphilis, complete urinalysis, ECG (electrocardiogram) and chest x-ray * Volunteers must have discontinued all pharmacological treatment at least two weeks before entering this trial * informed written consent, signed prior to the start of this trial
Exclusion criteria
* Volunteers requiring any kind of pharmacological treatment or having some known addiction * Volunteers having participated in any other clinical trial during the four preceding weeks * Volunteers who must start a treatment incompatible with this trial during its course * Volunteers who do not comply with the fasting requirements established in the trial or who do not comply with trial requirements such as avoiding intake of coffee, tea, cola soft drinks, etc. for 24 hours prior to the start of the trial * History of allergy or intolerance to Epinastine * Uncooperative volunteers * Previous participation in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the curve (AUC) of plasma concentration (CP) | Up to 24 hours after drug administration |
| Absorption rate Cpmax/AUC | Up to 24 hours after drug administration |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events | Up to 24 hours after last drug administration |
| Peak plasma concentration (Cpmax) | Up to 24 hours after drug administration |
| Time to peak (Tmax) | Up to 24 hours after drug administration |
| Number of participants with abnormal findings in physical examination | Up to 24 hours after last drug administration |
| Number of participants with clinically significant findings in vital signs | Up to 24 hours after last drug administration |
| Number of participants withdrawn or discontinued due to safety reasons | Up to 24 hours after last drug administration |
| Drug half - life (T1/2) | Up to 24 hours after drug administration |
Outcome results
None listed